PT3102577T - Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos - Google Patents
Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastosInfo
- Publication number
- PT3102577T PT3102577T PT15706577T PT15706577T PT3102577T PT 3102577 T PT3102577 T PT 3102577T PT 15706577 T PT15706577 T PT 15706577T PT 15706577 T PT15706577 T PT 15706577T PT 3102577 T PT3102577 T PT 3102577T
- Authority
- PT
- Portugal
- Prior art keywords
- growth factor
- factor receptor
- fibroblast growth
- receptor inhibitors
- quinolone derivatives
- Prior art date
Links
- 108091008794 FGF receptors Proteins 0.000 title 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000007660 quinolones Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937211P | 2014-02-07 | 2014-02-07 | |
| US201462007562P | 2014-06-04 | 2014-06-04 | |
| US201462069932P | 2014-10-29 | 2014-10-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3102577T true PT3102577T (pt) | 2018-10-23 |
Family
ID=52589764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT15706577T PT3102577T (pt) | 2014-02-07 | 2015-02-04 | Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US9815834B2 (enExample) |
| EP (1) | EP3102577B1 (enExample) |
| JP (1) | JP6553629B2 (enExample) |
| KR (1) | KR102046448B1 (enExample) |
| CN (1) | CN106459034B (enExample) |
| AU (1) | AU2015214328B2 (enExample) |
| BR (1) | BR112016017137B1 (enExample) |
| CA (1) | CA2937746C (enExample) |
| CY (1) | CY1121444T1 (enExample) |
| DK (1) | DK3102577T3 (enExample) |
| ES (1) | ES2689421T3 (enExample) |
| HU (1) | HUE041594T2 (enExample) |
| IL (1) | IL246933B (enExample) |
| MX (1) | MX369369B (enExample) |
| PL (1) | PL3102577T3 (enExample) |
| PT (1) | PT3102577T (enExample) |
| RU (1) | RU2721723C2 (enExample) |
| SI (1) | SI3102577T1 (enExample) |
| WO (1) | WO2015120049A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2689421T3 (es) | 2014-02-07 | 2018-11-14 | Principia Biopharma Inc. | Derivados de quinolina como inhibidores de los receptores de los factores de crecimiento de fibroblastos |
| KR20170032244A (ko) | 2014-07-26 | 2017-03-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도 |
| TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Ｃｒｔｈ２拮抗劑化合物及其用途 |
| CN118388481A (zh) * | 2015-08-11 | 2024-07-26 | 普林斯匹亚生物制药公司 | 用于制备fgfr抑制剂的方法 |
| CN108264510A (zh) * | 2017-01-02 | 2018-07-10 | 上海喆邺生物科技有限公司 | 一种选择性抑制激酶化合物及其用途 |
| SG11201907909TA (en) * | 2017-02-27 | 2019-09-27 | Betta Pharmaceuticals Co Ltd | Fgfr inhibitor and application thereof |
| CN110809576B (zh) * | 2017-03-03 | 2022-08-30 | 奥克兰联合服务有限公司 | Fgfr激酶抑制剂和药物用途 |
| WO2019015593A1 (zh) * | 2017-07-19 | 2019-01-24 | 江苏奥赛康药业股份有限公司 | 嘧啶并吡啶酮或者吡啶并吡啶酮类化合物及其应用 |
| WO2019029541A1 (zh) * | 2017-08-08 | 2019-02-14 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
| CN110016026B (zh) * | 2018-01-08 | 2022-11-25 | 上海凌济生物科技有限公司 | 一类具有抗肿瘤活性的嘧啶并吡啶酮类化合物、制备方法和用途 |
| JP7152794B2 (ja) * | 2018-09-14 | 2022-10-13 | アビスコ セラピューティクス カンパニー リミテッド | Ｆｇｆｒ阻害剤、その製造方法および応用 |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| SG11202111533XA (en) * | 2019-04-19 | 2021-11-29 | Pfizer | Anti-proliferative agents for treating pah |
| ES3007814T3 (en) | 2019-08-08 | 2025-03-20 | Zhangzhou Pien Tze Huang Pharm | Pyrazine-2(1h)-ketone compound preparation method |
| WO2021108803A1 (en) | 2019-11-26 | 2021-06-03 | Theravance Biopharma R&D Ip, Llc | Fused pyrimidine pyridinone compounds as jak inhibitors |
| CN119013260A (zh) * | 2022-03-31 | 2024-11-22 | 优领医药科技(香港)有限公司 | 螺双环化合物 |
| CN115368219B (zh) * | 2022-10-25 | 2022-12-27 | 苏州康纯医药科技有限公司 | 一种fgfr抑制剂关键中间体的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| WO2004063195A1 (en) * | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| ATE356124T1 (de) | 2003-11-13 | 2007-03-15 | Hoffmann La Roche | Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7- one |
| WO2005105097A2 (en) | 2004-04-28 | 2005-11-10 | Gpc Biotech Ag | Pyridopyrimidines for treating inflammatory and other diseases |
| WO2006082492A1 (en) | 2005-02-02 | 2006-08-10 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as anti-inflammatory agents |
| WO2008150260A1 (en) | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| IT1395724B1 (it) | 2009-02-25 | 2012-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| CN102219860B (zh) * | 2011-05-20 | 2012-09-12 | 烟台荣昌生物工程有限公司 | FGFR-Fc融合蛋白及其用途 |
| WO2013067423A1 (en) * | 2011-11-04 | 2013-05-10 | Afraxis, Inc. | Pak inhibitors for the treatment of cell proliferative disorders |
| CA2878412A1 (en) * | 2012-07-11 | 2014-01-16 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| EP2994470B1 (en) | 2013-05-09 | 2018-04-18 | Principia Biopharma Inc. | Pyrido[2,3-d]pyrimidine derivatives as fibroblast growth factor inhibitors |
| US9851834B2 (en) | 2013-09-10 | 2017-12-26 | Alsentis, Llc | Time domain differential techniques to characterize various stimuli |
| ES2689421T3 (es) | 2014-02-07 | 2018-11-14 | Principia Biopharma Inc. | Derivados de quinolina como inhibidores de los receptores de los factores de crecimiento de fibroblastos |
| WO2016191172A1 (en) | 2015-05-22 | 2016-12-01 | Principia Biopharma Inc. | Quinolone derivatives as fibroblast growth factor receptor inhibitors |
| CN118388481A (zh) | 2015-08-11 | 2024-07-26 | 普林斯匹亚生物制药公司 | 用于制备fgfr抑制剂的方法 |
-
2015
- 2015-02-04 ES ES15706577.2T patent/ES2689421T3/es active Active
- 2015-02-04 JP JP2016550703A patent/JP6553629B2/ja active Active
- 2015-02-04 PT PT15706577T patent/PT3102577T/pt unknown
- 2015-02-04 EP EP15706577.2A patent/EP3102577B1/en active Active
- 2015-02-04 DK DK15706577.2T patent/DK3102577T3/en active
- 2015-02-04 RU RU2016130932A patent/RU2721723C2/ru active
- 2015-02-04 BR BR112016017137-3A patent/BR112016017137B1/pt active IP Right Grant
- 2015-02-04 PL PL15706577T patent/PL3102577T3/pl unknown
- 2015-02-04 AU AU2015214328A patent/AU2015214328B2/en active Active
- 2015-02-04 MX MX2016010106A patent/MX369369B/es active IP Right Grant
- 2015-02-04 CA CA2937746A patent/CA2937746C/en active Active
- 2015-02-04 HU HUE15706577A patent/HUE041594T2/hu unknown
- 2015-02-04 CN CN201580007653.5A patent/CN106459034B/zh active Active
- 2015-02-04 SI SI201530358T patent/SI3102577T1/sl unknown
- 2015-02-04 KR KR1020167021267A patent/KR102046448B1/ko active Active
- 2015-02-04 US US15/022,869 patent/US9815834B2/en active Active
- 2015-02-04 WO PCT/US2015/014460 patent/WO2015120049A1/en not_active Ceased
-
2016
- 2016-03-22 US US15/077,442 patent/US9567334B2/en active Active
- 2016-07-25 IL IL246933A patent/IL246933B/en active IP Right Grant
-
2017
- 2017-11-08 US US15/806,525 patent/US10294223B2/en active Active
-
2018
- 2018-10-18 CY CY20181101070T patent/CY1121444T1/el unknown
-
2019
- 2019-04-12 US US16/383,237 patent/US11078199B2/en active Active
-
2021
- 2021-05-03 US US17/306,528 patent/US20210292323A1/en not_active Abandoned
-
2023
- 2023-06-30 US US18/217,002 patent/US12162882B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL246933B (en) | History of quinolones as fibroblast growth factor receptor inhibitors | |
| IL247970A (en) | Quinoline history as smo inhibitors | |
| IL254190A0 (en) | History of tricyclic bactericides | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| IL244738A0 (en) | Inhibitors of the fibroblast growth factor receptor | |
| IL248550A0 (en) | History of indolin-2-one or pyrrolo-pyridin-2-one | |
| IL248789A0 (en) | History of quinazolinones as phosphatidylinositol 3-kinase inhibitors | |
| ZA201802411B (en) | Indolin-2-one derivatives | |
| IL249674B (en) | Quinolizinone derivatives as inhibitors of pi3k | |
| ZA201700883B (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| IL258438B (en) | 2-Aminoquinoline derivatives as p70s6 kinase inhibitors | |
| TH1601002358A (th) | ตัวยับยั้งไฟโบรบลาสต์ โกรท แฟคเตอร์ รีเซปเตอร์ |